ImaginAb and Minerva announce a new supply agreement to offer CD8 ImmunoPET imaging agent
ImaginAb and Minerva Imaging announce a new supply agreement to offer ImaginAb’s investigational CD8 ImmunoPET imaging agent for preclinical and clinical research
Los Angeles, California, USA, and Ølstykke, Denmark, June 26, 2023
ImaginAb Inc., a market leading global biotechnology company focused on developing next generation ImmunoPET imaging agents and therapeutic radiopharmaceuticals (RPT), and Minerva Imaging, a leading preclinical CRO and CDMO in oncology, targeted radiopharmaceuticals and molecular imaging today announced an agreement to supply ImaginAb’s investigational CD8 ImmunoPETTM agent (89Zrcrefmirlimab berdoxam) for use in clinical trials and preclinical research projects.
Immuno-oncology has proven to be an effective way of treating cancer in the past decade. There is a growing interest from biotech and pharmaceutical companies that impacts the advancement of new improved, and lifesaving drugs for seriously ill cancer patients. ImaginAb’s CD8 ImmunoPET agent is designed to provide insight into the immune system, which may be able to help to inform early decision-making in clinical trials and preclinical research.
Carsten Nielsen, CEO and co-founder of Minerva Imaging, said:
We are thrilled with the agreement with ImaginAb, enabling us to excel in delivering customized cancer research. The integration of ImaginAb’s CD8 ImmunoPET into our molecular imaging services significantly enhances our ability to provide essential information in an early stage of drug development with the ability to incorporate the same imaging biomarker across clinical trials.”
Ian Wilson, Chief Executive Officer of ImaginAb, said:
At ImaginAb, we prioritize listening to the needs of our clinical development partners. The agreement with Minerva increases access to our investigational CD8 ImmunoPET agent with Minerva providing its services to pharmaceutical companies that are researching and developing new immunotherapy products.
For further information please contact:
Marketing and Business Intelligence Manager
Phone: +1 310 645 1211
Carsten H. Nielsen
Co-founder and CEO
Phone: +45 27124971
A clinical stage, revenue-generating global biotechnology company developing next-generation imaging agents and radiopharmaceutical therapy products through its proprietary minibody and cys-diabody platforms. The lead candidate, CD8 ImmunoPET™, is currently in Phase II clinical trials and has been licensed by pharmaceutical and biotech companies for use in immunotherapy clinical trials.
For more information, visit www.imaginab.com
About CD8 ImmunoPET™ (89Zr crefmirlimab berdoxam)
An 89Zr-labeled minibody that has been designed to bind to the CD8 receptor on human T cells for quantitative, non-invasive PET imaging. This method is currently being researched to determine whether it may be used to diagnose the immune status of a patient, to measure the efficacy of immunotherapies, and to predict patient outcomes.
About Minerva Imaging
Minerva Imaging is a scientifically driven CRO/CDMO founded in 2011, and currently counting over 130 employees. The company focuses on the use of advanced animal models within oncology and cardiovascular diseases and in vivo molecular imaging for translational research and drug development. Minerva Imaging engages with its collaborators to understand their scientific questions and discuss how its methods and capabilities can provide answers.
Follow us on LinkedIn for the latest news updates or visit www.minervaimaging.com for more information.